A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, 3-Way Crossover Study To Determine The Effects Of Inhaled Doses Of PF-03526299 On Allergen-Induced Airway Responses In Mild Asthmatic Subjects.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2010
At a glance
- Drugs Fluticasone propionate; PF 3526299
- Indications Asthma
- Focus Therapeutic Use
- 27 Sep 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 27 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Oct 2009 Planned number of patients changed from 12 to 36 as reported by ClinicalTrials.gov.